Evidence method
Level · gp.fundamentals.debt_to_revenue
128.48% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Jun 30, 2019
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-19-038053General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.01% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
8.73% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
15.00% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
83.33% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
71.24% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
17.09% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
10.62% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
4.77% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 131.87%
- Current
- 128.48%
- Delta
- -3.40%
- Previous
- 3.36%
- Current
- 3.01%
- Delta
- -0.35%
- Previous
- 27.02%
- Current
- 8.73%
- Delta
- -18.29%
- Previous
- 13.78%
- Current
- 15.00%
- Delta
- 1.22%
- Previous
- 79.48%
- Current
- 83.33%
- Delta
- 3.86%
- Previous
- 72.16%
- Current
- 71.24%
- Delta
- -0.92%
- Previous
- 8.32%
- Current
- 17.09%
- Delta
- 8.77%
- Previous
- 8.27%
- Current
- 10.62%
- Delta
- 2.35%
- Previous
- 3.23%
- Current
- 4.77%
- Delta
- 1.54%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_INCREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.